

DALM 2007

XVI International Symposium on DRUGS AFFECTING LIPID METABOLISM

New York, NY (USA), October 4-7, 2007

Chairpersons: **A.M. Gotto, Jr.** (USA) – **R. Paoletti** (Italy)

Scientific Program Committee: **C.M. Ballantyne** (USA) – **A.L. Catapano** (Italy) – **H.N. Ginsberg** (USA)

Scientific Secretary: **S. Bellosta** (Italy)

INTERNATIONAL ADVISORY BOARD

Assmann G. (Germany) - **Auwerx J.** (France) - **Badimon L.** (Spain) - **Barter P.J.** (Australia) - **Beisiegel U.** (Germany) - **Bernini F.** (Italy) - **Betteridge J.** (UK) - **Brewer H.B.** (USA) - **Brown G.** (USA) - **Brown W.V.** (USA) - **Buse J.** (USA) - **Calandra S.** (Italy) - **Chapman M.J.** (France) - **Chiariello M.** (Italy) - **Corsini A.** (Italy) - **Crepaldi G.** (Italy) - **Davidson M.** (USA) - **Davignon J.** (Canada) - **De Backer G.** (Belgium) - **DeFronzo R.** (USA) - **Després J.P.** (Canada) - **Ehnholm C.** (Finland) - **Erhardt L.R.** (Sweden) - **Faergeman O.** (Denmark) - **Farnier M.** (France) - **Fellin R.** (Italy) - **Ferrannini E.** (Italy) - **Fisher E.A.** (USA) - **Franceschini G.** (Italy) - **Fruchart J.-C.** (France) - **Fuster V.** (USA) - **Gaddi A.** (Italy) - **Galli C.** (Italy) - **Ganz P.** (USA) - **Goldberg I.** (USA) - **Greten H.** (Germany) - **Grundy S.** (USA) - **Haffner S.M.** (USA) - **Hajjar D.** (USA) - **Hamsten A.** (Sweden) - **Hancu N.** (Romania) - **Hobbs H.** (USA) - **Juhan-Vague I.** (France) - **Kanjuh V.** (Yugoslavia) - **Kastelein J.J.P.** (The Netherlands) - **Katan M.B.** (The Netherlands) - **Kipshidze N.** (Republic of Georgia) - **Kita T.** (Japan) - **Kovanen P.** (Finland) - **Krauss R.M.** (USA) - **LaRosa J.C.** (USA) - **Leitersdorf E.** (Israel) - **Lenfant C.** (USA) - **Libby P.** (USA) - **Lüscher T.** (Switzerland) - **Mahley R.** (USA) - **Mancini M.** (Italy) - **Manzato E.** (Italy) - **Masri B.** (USA) - **Matsuzawa Y.** (Japan) - **Mezzetti A.** (Italy) - **Modena M.G.** (Italy) - **Naruszewicz M.** (Poland) - **Nielsen L.B.** (Denmark) - **Nissen S.E.** (USA) - **Nosedà G.** (Switzerland) - **Notarbartolo A.** (Italy) - **Novo S.** (Italy) - **O'Brien R.** (Australia) - **Olsson A.G.** (Sweden) - **Packard C.J.** (UK) - **Park J.E.** (Korea) - **Patrono C.** (Italy) - **Patsch J.R.** (Austria) - **Pearson T.A.** (USA) - **Pedersen T.** (Norway) - **Plutzky J.** (USA) - **Poli A.** (Italy) - **Rader D.** (USA) - **Ridker P.** (USA) - **Riesen W.** (Switzerland) - **Rubinstein A.** (Israel) - **Sacks F.** (USA) - **Saito Y.** (Japan) - **Santamarina-Fojo S.** (USA) - **Schaefer E.J.** (USA) - **Shepherd J.** (UK) - **Sirtori C.R.** (Italy) - **Smirnov V. N.** (Russia) - **Staels B.** (France) - **Stein Y.** (Israel) - **Steiner G.** (Canada) - **Stoffel M.** (USA) - **Stone N.J.** (USA) - **Szollar L.** (Hungary) - **Tall A.** (USA) - **Taskinen M.-R.** (Finland) - **Thiene G.** (Italy) - **Tokgozoglul L.** (Turkey) - **Tonkin A.M.** (Australia) - **Tremoli E.** (Italy) - **Volpe R.** (Italy) - **Von Eckardstein A.** (Switzerland) - **Watson K.E.** (USA) - **Watts G.** (Australia) - **Wenger N.K.** (USA) - **Wilson P.** (USA) - **Yang Y.** (China) - **Zambon A.** (Italy)

GOALS AND OBJECTIVES OF THE SYMPOSIUM

The goal of the Symposium is to present the state of the art in both research and current therapies for treatment and prevention of atherosclerosis and other cardiovascular diseases, thereby enhancing patient outcome. At the conclusion of this activity, participants should be able to: 1) Assess the benefits of lipid modification in clinical trials on endpoints of cardiovascular events and surrogate endpoints such as progression/regression of atherosclerosis and endothelial dysfunction; 2) Evaluate the importance of traditional and novel risk factors, including genetic polymorphisms, as they relate to atherosclerosis and cardiovascular disease and contribute to the response to drug therapy; 3) Differentiate the multiple effects of various classes of medication, alone and in combination, on lipid modification and measures of vascular function and disease; 4) Appraise new drugs, neutraceuticals, and dietary approaches and their application to the treatment of lipid disorders; 5) Evaluate the role of new technologies (such as CT, MRI, and IVUS) and new biochemical markers in identifying the atherosclerotic burden and the vulnerable plaque; 6) Review and evaluate new research regarding the underlying and environmental causes of the metabolic syndrome; 7) Assess the role of the cardiovascular and metabolic risk factors in the development of cardiovascular disease and diabetes in special groups of patients; 8) Describe recent clinical trials and assess their impact on the prevention and treatment of atherosclerosis and cardiovascular disease; and 9) Determine the practical basis for the appropriate use and the implementation of guidelines.

SCIENTIFIC PROGRAM

The SCIENTIFIC PROGRAM will include: Plenary Sessions, Workshops, Supported Symposia, Debates, Oral Communications and Poster Sessions for submitted papers.

Plenary Sessions

HDL • Formation and Progression of the Atherosclerotic Plaque: from Biology to Clinic • New Challenges in Hypolipidemic Therapy • Nutrition, Obesity, Diabetes, and Cardiovascular Disease

Debates

PPARs • Pharmacological Therapy: Increasing HDL vs Lowering LDL

Workshops and Poster Sessions

Atherosclerotic Plaque (Endothelial cells; Extracellular matrix; Imaging; Inflammation; Macrophages; Plaque stability; Smooth muscle cells; Immune system; Platelets; Mast cells) • **Clinical Practice** (Pharmacoeconomy; Pharmacovigilance; Gender specific issues; Elderly; Patients with kidney disease; Peripheral vascular disease; Stroke; Thrombosis) • **Drug Efficacy and Safety** (Drug synthesis; Drug efficacy; Drug interaction) • **Genetics** (Genetic polymorphism in CVD; Genetic dyslipidemias) • **HDL and Reverse Cholesterol Transport** (Cholesterol transporters; ABCA1; ApoA1 receptors; SRBI) • **New Challenges in Hypolipidemic Therapy** (Drug efficacy and safety; Hepatic steatosis and NASH; Nuclear receptors and lipid metabolism) • **Lipid Lowering Therapy** (Combination therapy; Drugs affecting HDL; Drugs affecting LDL; Drugs affecting lipid metabolism; Drugs affecting triglycerides; Drug metabolism) • **Metabolic Syndrome** (Definition; Diabetes; Hyperglycemia; Insulin resistance and lipotoxicity; Adipose tissue; Pharmacotherapy) • **New Approaches to CVD** (Gene therapy; Stem cells) • **Nutrition and CVD** (Antioxidants; Dietary components; Fatty acids; Omega-3; Obesity; Phytosterols; Vegetable proteins; Alcohol; Fibers)

The Advance Program (with information on Registration and Abstract submission) will be mailed in March 2007.

The deadline for Abstract submission will be May 20, 2007

SCIENTIFIC - ORGANIZING SECRETARIATS

Main Office:

DALM 2007

Giovanni Lorenzini Medical Foundation

6535 Fannin, M.S. A-601

Houston, Texas 77030 (USA)

Phone: (+1) 713-797-0401

Fax: (+1) 713-796-8853

E-mail: dalm@bcm.tmc.edu

Branch Office:

DALM 2007

Fondazione Giovanni Lorenzini

Medical Science Foundation

Via A. Appiani, 7 – 20121 Milan (Italy)

Phone: (+ 39) 02-29006267

Fax: (+39) 02-29007018

E-mail: dalm@lorenzinifoundation.org

Congress website: www.lorenzinifoundation.org
(please check the website for updates)

XVI INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM NEW YORK, NY (USA) OCTOBER 4-7, 2007

REQUEST FOR FURTHER INFORMATION

(Complete this form in capital letters and send by fax, mail, or e-mail by February 1, 2007)

Please keep my name on the mailing list for the Advance Program:

FAMILY NAME _____ GIVEN NAME(S) _____

NAME OF INSTITUTION _____

STREET: _____ CITY: _____ STATE: _____

COUNTRY: _____ POSTAL CODE: _____

PHONE: _____ TELEFAX: _____

E-MAIL: _____

I wish to receive _____ copy/copies of the Advance Program

I plan to send an abstract:

Oral Communication

Poster

Date _____ Signature _____

Please send your request to: **DALM 2007 - GIOVANNI LORENZINI MEDICAL FOUNDATION**
6535 Fannin, MS A- 601, Houston, Texas 77030-2704 (USA) – Fax: (+1) 713-796-8853 –
E-mail: dalm@bcm.tmc.edu